Compare CRSP & AQN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRSP | AQN |
|---|---|---|
| Founded | 2013 | 1988 |
| Country | Switzerland | Canada |
| Employees | N/A | 3786 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.8B |
| IPO Year | 2016 | N/A |
| Metric | CRSP | AQN |
|---|---|---|
| Price | $46.25 | $6.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 7 |
| Target Price | ★ $70.29 | $6.57 |
| AVG Volume (30 Days) | 1.9M | ★ 4.0M |
| Earning Date | 05-05-2026 | 03-06-2026 |
| Dividend Yield | N/A | ★ 4.04% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $289,590,000.00 | N/A |
| Revenue This Year | $1,082.59 | $3.34 |
| Revenue Next Year | $87.74 | $4.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9169.85 | N/A |
| 52 Week Low | $30.06 | $4.45 |
| 52 Week High | $78.48 | $7.11 |
| Indicator | CRSP | AQN |
|---|---|---|
| Relative Strength Index (RSI) | 37.01 | 39.05 |
| Support Level | N/A | $5.80 |
| Resistance Level | $60.63 | $6.59 |
| Average True Range (ATR) | 2.49 | 0.19 |
| MACD | -1.08 | -0.03 |
| Stochastic Oscillator | 1.70 | 27.62 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Algonquin Power & Utilities Corp is a Canada-based diversified international generation, transmission, and distribution company. The company's operations are organized across two business units: the Regulated Services Group, which owns and operates a portfolio of regulated electric, water distribution, and wastewater collection, and natural gas utility systems and transmission operations in the United States, Canada, Bermuda, and Chile; and the Hydro Group, which consists of hydroelectric-generating facilities located in Canada. It generates the majority of its revenue from the Regulated Services Group segment.